Ane S: IL-3 signaling plus the function of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 2000, 19(21):2532?547. 30. Ernst M, Jenkins BJ: Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet 2004, 20(1):23?2. 31. Fiszer-Kierzkowska A, Vydra N, Wysocka-Wycisk A, Kronekova Z, Jarzab M, Lisowska KM, Krawczyk Z: Liposome-based DNA carriers may perhaps induce cellular tension response and transform gene expression pattern in transfected cells. BMC Mol Biol 2011, 12:27. 32. Song L, Turkson J, Karras JG, Jove R, Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene 2003, 22(27):4150?165. 33. Schust J, Sperl B, Hollis A, Mayer TU, Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 2006, 13(11):1235?242. 34. Kalluri R, Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119(6):1420?428.Fmoc-Gly-OH Chemical name 35. Strutz F, Zeisberg M, Ziyadeh FN, Yang CQ, Kalluri R, Muller GA, Neilson EG: Part of fundamental fibroblast growth factor-2 in epithelial-mesenchymal transformation.876379-79-2 In stock Kidney Int 2002, 61(5):1714?728. 36. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA: The transcription element snail controls epithelialmesenchymal transitions by repressing E-cadherin expression.PMID:23613863 Nat Cell Biol 2000, 2(2):76?three. 37. Vernon AE, LaBonne C: Tumor metastasis: a brand new twist on epithelialmesenchymal transitions. Curr Biol 2004, 14(17):R719 721. 38. Thiery JP: Epithelial-mesenchymal transitions in improvement and pathologies. Curr Opin Cell Biol 2003, 15(six):740?46. 39. Carmeliet P, Jain RK: Angiogenesis in cancer as well as other diseases. Nature 2000, 407(6801):249?57. 40. Folkman J: Part of angiogenesis in tumor development and metastasis. Semin Oncol 2002, 29(six Suppl 16):15?eight. 41. Tonini T, Rossi F, Claudio PP: Molecular basis of angiogenesis and cancer. Oncogene 2003, 22(42):6549?556. 42. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J: Vascular-specific growth elements and blood vessel formation. Nature 2000, 407(6801):242?48. 43. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM: Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest 1996, 97(12):2792?802. 44. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Morris SB, Xue YY, Burdick MD, Glass MC, Iannettoni MD, Strieter RM: Epithelial-neutrophil activating peptide (ENA-78) is definitely an critical angiogenic element in non-small cell lung cancer. J Clin Invest 1998, 102(3):465?72.Kachroo et al. Journal of Experimental Clinical Cancer Research 2013, 32:97 http://jeccr/content/32/1/Page 14 of45. Battle TE, Lynch RA, Frank DA: Signal transducer and activator of transcription 1 activation in endothelial cells is actually a damaging regulator of angiogenesis. Cancer Res 2006, 66(7):3649?657. 46. von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, Wiedenmann B, Hocker M, Rosewicz S: Effects of interferon alpha on vascular endothelial development factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95(6):437?48. 47. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE: HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complicated that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24(19):3110?120. 48. Laver T.
